Traws Pharma (TRAW) awards 274,000 stock options to CEO Dukes

Rhea-AI Filing Summary

Traws Pharma, Inc. granted its Chief Executive Officer and director, Iain D. Dukes, stock options covering 274,000 shares of common stock with an exercise price of $0.68 per share under its 2021 Incentive Compensation Plan.

The options vest 100% on the first anniversary of the July 9, 2026 grant date and expire on July 9, 2036, leaving Dukes holding 274,000 options following this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dukes Iain D.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	274,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 274,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options Granted: 274,000 options Exercise Price: $0.68 per share Expiration Date: July 9, 2036 +3 more

6 metrics

Options Granted 274,000 options Stock options awarded to CEO Iain D. Dukes on July 9, 2026

Exercise Price $0.68 per share Exercise price for the 274,000 stock options

Expiration Date July 9, 2036 Expiration of stock options granted to CEO

Vesting Date July 9, 2027 Options vest 100% on first anniversary of grant date

Underlying Shares 274,000 shares Common shares underlying the stock option award

Post-Grant Holdings 274,000 options Total options held directly by CEO after this award

Key Terms

Stock Option (right to buy), 2021 Incentive Compensation Plan, vesting

3 terms

Stock Option (right to buy) financial

"Security title listed as Stock Option (right to buy) with underlying common stock"

2021 Incentive Compensation Plan financial

"Awarded by the compensation committee under the Issuer's 2021 Incentive Compensation Plan"

vesting financial

"The stock options under this award will vest 100% on the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/14/2026 - 08:26 PM Accepted by SEC EDGAR 07/14/2026 - 08:26 PM Learn about SEC filing dates

FAQ

What insider transaction did Traws Pharma (TRAW) disclose for CEO Iain D. Dukes?

Traws Pharma disclosed that CEO Iain D. Dukes received stock options for 274,000 common shares at an exercise price of $0.68 per share. The grant was made on July 9, 2026 under the company’s 2021 Incentive Compensation Plan.

What is the exercise price of the new Traws Pharma (TRAW) stock options granted to the CEO?

The stock options granted to CEO Iain D. Dukes carry an exercise price of $0.68 per share. This price applies to all 274,000 underlying common shares covered by the award made on July 9, 2026.

When do CEO Iain D. Dukes’ Traws Pharma (TRAW) stock options vest?

The options granted to CEO Iain D. Dukes vest 100% on July 9, 2027, the first anniversary of the grant date. Until that vesting date, the full 274,000 option shares remain unvested under the 2021 Incentive Compensation Plan.

How many Traws Pharma (TRAW) shares are covered by the CEO’s new option grant?

The new stock option award to CEO Iain D. Dukes covers 274,000 shares of Traws Pharma common stock. Following this grant, he holds 274,000 stock options directly, each exercisable for one share upon vesting.

When do the Traws Pharma (TRAW) stock options granted to CEO Dukes expire?

The stock options granted to CEO Iain D. Dukes expire on July 9, 2036. This provides a ten-year term from the July 9, 2026 grant date for him to exercise the 274,000 options after they vest on July 9, 2027.

Under which plan were the Traws Pharma (TRAW) CEO stock options granted?

The options were awarded under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated through the grant date. The company’s compensation committee, composed of independent directors, approved the 274,000-share stock option grant to CEO Iain D. Dukes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dukes Iain D.

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PENNSYLVANIA 18940

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.68	07/09/2026		A		274,000		07/09/2027(1)	07/09/2036	Common Stock	274,000	$0	274,000	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Iain Dukes	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)